Division of Pediatric Neurosurgery, Department of Neurosurgery, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.
Dev Med Child Neurol. 2018 Oct;60(10):1038-1044. doi: 10.1111/dmcn.13730. Epub 2018 Mar 23.
To describe 30-day outcomes after intrathecal baclofen (ITB) pump placement in children and identify risk factors for readmission, reoperation, and perioperative complication using the National Surgical Quality Improvement Program-Pediatric (NSQIP-P) database.
Patients aged 0 to 18 years who underwent ITB pump placement (2012-2014) comprised the study cohort defined in the database. Multivariate regression analysis was performed using preoperative and perioperative data from the American College of Surgeons' NSQIP-P database. Outcomes of interest within 30 days of surgery were (1) unplanned reoperation; (2) unplanned readmission; and (3) composite postoperative event, including complication, reoperation, and/or readmission.
We identified 423 surgeries; 246 (58.2%) patients were male, 177 (41.8%) patients were female. Median age was 12 years and 11 months. Median operative time was 70 minutes (interquartile range 56-97min). Mean length of stay was 3.8 days. The patient population had a high number of medical comorbidities. The overall readmission rate was 7.3%; mean postoperative admission date was 14.1 days after surgery. Of readmitted patients, 64.5% underwent reoperation. The most common indication for reoperation was surgical site infection. Female sex was associated with decreased risk of readmission (odds ratio [OR] 0.25, 95% confidence interval [CI] 0.09-0.65; p=0.01); American Society of Anesthesiologists Classification of greater than or equal to 3 was associated with decreased risk of unplanned return to surgery (OR 0.26, 95% CI 0.11-0.66; p=0.04); length of stay greater than or equal to 3 days at index surgery was associated with increased risk of composite 30-day perioperative event (OR 2.33, 95% CI 1.29-4.20; p=0.01).
Our data provide national perspectives on 30-day perioperative outcomes for ITB pump placement in children. Results illustrate NSQIP-P database collection methodology and highlight opportunities for quality improvement in clinical practice.
Seven percent of patients who underwent intrathecal baclofen pump placement required readmission within 30 days. The most common indication for reoperation was surgical site infection.
利用美国外科医师学会全国手术质量改进计划-儿科(NSQIP-P)数据库,描述鞘内注射巴氯芬(ITB)泵植入后 30 天的结果,并确定再入院、再次手术和围手术期并发症的风险因素。
本研究纳入了数据库中年龄在 0 至 18 岁之间接受 ITB 泵植入(2012-2014 年)的患者。使用美国外科医师学会 NSQIP-P 数据库的术前和围手术期数据,对患者进行多变量回归分析。术后 30 天内的研究结果包括(1)计划外再次手术;(2)计划外再入院;以及(3)包括并发症、再次手术和/或再入院的复合术后事件。
我们共确定了 423 例手术;246 例(58.2%)患者为男性,177 例(41.8%)患者为女性。中位年龄为 12 岁 11 个月。中位手术时间为 70 分钟(四分位距 56-97 分钟)。平均住院时间为 3.8 天。该患者人群存在大量的合并症。总体再入院率为 7.3%;平均术后入院日期为术后 14.1 天。再入院患者中有 64.5%再次接受了手术。再次手术最常见的指征是手术部位感染。女性与较低的再入院风险相关(比值比 [OR] 0.25,95%置信区间 [CI] 0.09-0.65;p=0.01);美国麻醉医师协会分类≥3 与较低的计划外再次手术风险相关(OR 0.26,95%CI 0.11-0.66;p=0.04);索引手术时住院时间≥3 天与复合 30 天围手术期事件的风险增加相关(OR 2.33,95%CI 1.29-4.20;p=0.01)。
我们的数据为儿童 ITB 泵植入后 30 天围手术期结果提供了全国性的观点。结果说明了 NSQIP-P 数据库的收集方法,并强调了临床实践中质量改进的机会。
7%接受鞘内注射巴氯芬泵植入的患者在 30 天内需要再次入院。再次手术最常见的指征是手术部位感染。